The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of eribulin and pembrolizumab in patients (pts) with metastatic soft tissue sarcomas (STS): Report of LMS cohort.
 
Michael Nathenson
No Relationships to Disclose
 
Edwin Choy
Consulting or Advisory Role - Immune Design
Research Funding - Amgen (Inst); AstraZeneca (Inst); Exelixis (Inst); Immune Design (Inst); Iterion Therapeutics (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst)
 
Neena D Carr
No Relationships to Disclose
 
Hayley D Hibbard
Travel, Accommodations, Expenses - SpringWorks Therapeutics
 
Emanuele Mazzola
No Relationships to Disclose
 
Paul J. Catalano
No Relationships to Disclose
 
Katherine Anne Thornton
Consulting or Advisory Role - Adaptimmune; Agios; Lilly; Macrogenics; More Health
Expert Testimony - Kilcoyne & Nesbitt
 
Jeffrey A. Morgan
No Relationships to Disclose
 
Gregory Michael Cote
Consulting or Advisory Role - Agios; Epizyme; PharmaMar
Research Funding - Agios (Inst); Bavarian Nordic; Bayer (Inst); Boston Biomedical (Inst); CBA Research (Inst); Eisai (Inst); Epizyme (Inst); Macrogenics (Inst); Merck KGaA (Inst); PharmaMar (Inst); Plexxikon (Inst); Springworks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Priscilla Merriam
Consulting or Advisory Role - Lilly
 
Andrew J. Wagner
Honoraria - Novartis
Consulting or Advisory Role - Daiichi Sankyo; Deciphera; Five Prime Therapeutics; Lilly; Loxo
Research Funding - AADi (Inst); Daiichi Sankyo (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst)
 
George D. Demetri
Leadership - Blueprint Medicines; Merrimack; Translate BIO
Stock and Other Ownership Interests - Bessor Pharma; Blueprint Medicines; Caprion/HistoGeneX; Caris Life Sciences; Champions Oncology; Erasca, Inc; G1 Therapeutics; Merrimack; Relay Therapeutics; Translate BIO
Consulting or Advisory Role - Acrivon Therapeutics; Adaptimmune; Arsenal Capital; Bayer; Blueprint Medicines; Caprion/HistoGeneX; Caris Life Sciences; Daiichi Sankyo; EMD Serono; Epizyme; G1 Therapeutics; ICON Clinical Research; Ignyta; Janssen Oncology; Loxo; Medscape; Mirati Therapeutics; MJH Associates; Novartis; Pfizer; PharmaMar; Polaris; Relay Therapeutics; Roche/Genentech; Sanofi; WIRB-Copernicus Group; ZIOPHARM Oncology
Research Funding - AbbVie (Inst); Abbvie (Inst); Adaptimmune (Inst); Bayer (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Janssen Oncology (Inst); Loxo (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent on use of imatinib for GIST, receive minor royalty payment from Dana-Farber after license between Dana-Farber and Novartis
Expert Testimony - Epizyme
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories; Allergan (I)
Consulting or Advisory Role - Bayer; Blueprint Medicines; Daiichi Sankyo; deciphera; Lilly; MORE Health; Research to Practice; UpToDate
Research Funding - ARIAD (Inst); Bayer (Inst); Blueprint Medicines (Inst); Deciphera (Inst); Novartis (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate
Expert Testimony - Bayer
Other Relationship - Research to Practice